AstraZeneca Pharma India Limited — Important, 14-07-2025: General Updates

AstraZeneca Pharma India has secured regulatory approval to market its oncology drug Imfinzi for an additional indication. The expanded use covers adult patients with muscle invasive bladder cancer (MIBC), where Imfinzi will be used in combination with gemcitabine and cisplatin, followed by single-agent treatment. This significant business development allows for the import and sale of Imfinzi for this new indication in India, opening up a new market segment and enhancing the drug's commercial potential.